BAKER BROS. ADVISORS LP Q4 2021 Filing
Filed February 14, 2022
Portfolio Value
$20.6B
Holdings
121
Report Date
Q4 2021
Filing Type
13F-HR
All Holdings (121 positions)
| Stock | Value |
|---|---|
SGENUSDSeagen Inc. | $7.2T |
ONCBeiGene, Ltd. | $3.2T |
INCYIncyte Corporation | $2.5T |
KODKodiak Sciences Inc. | $1.2T |
ACADACADIA Pharmaceuticals Inc. | $978.2B |
BMRNBioMarin Pharmaceutical Inc. | $673.3B |
ASNDAscendis Pharma A/S | $611.0B |
ARGXargenx SE | $392.1B |
MRTXEURMirati Therapeutics, Inc. | $206.8B |
BCRXBioCryst Pharmaceuticals, Inc. | $176.0B |
KYMRKymera Therapeutics, Inc. | $151.4B |
NVTA1EURInvitae Corporation | $150.8B |
ABCLAbCellera Biologics Inc. | $149.4B |
MDGLMadrigal Pharmaceuticals, Inc. | $127.0B |
PRLDPrelude Therapeutics Inc. | $126.0B |
LEGNLegend Biotech Corporation | $116.0B |
PACBPacific Biosciences of California, Inc. | $111.4B |
GBTUSDGlobal Blood Therapeutics, Inc. | $97.0B |
CERSCerus Corporation | $93.4B |
1K0IGM Biosciences, Inc. | $92.6B |
IMCRImmunocore Holdings plc | $86.3B |
TVTXTravere Therapeutics, Inc. | $82.8B |
TRDAEntrada Therapeutics, Inc. | $80.5B |
HRTXHeron Therapeutics, Inc. | $74.2B |
AMRNAmarin Corporation plc | $71.3B |
NRIXNurix Therapeutics, Inc. | $71.0B |
TILInstil Bio, Inc. | $66.6B |
MRUSMerus N.V. | $64.8B |
HZNPHorizon Therapeutics Public Ltd Co | $64.6B |
IMTXImmatics N.V. | $59.5B |
CCXIEURChemoCentryx, Inc. | $59.4B |
IM8NInsmed Incorporated | $58.7B |
NBIXNeurocrine Biosciences, Inc. | $57.7B |
KRYSKrystal Biotech, Inc. | $56.5B |
VERVVerve Therapeutics, Inc. | $52.2B |
APLS 3.5 09/15/26Apellis Pharmaceuticals, Inc. | $48.0B |
VSTMVerastem, Inc. | $44.1B |
INSM 0.75 06/01/28Insmed Incorporated | $43.3B |
SRPT 1.5 11/15/24Sarepta Therapeutics, Inc. | $42.7B |
RYTMRhythm Pharmaceuticals, Inc. | $38.6B |
290AChinook Therapeutics, Inc. | $38.1B |
RAREUltragenyx Pharmaceutical Inc. | $37.4B |
ADAPYAdaptimmune Therapeutics plc | $36.9B |
ALKSAlkermes plc | $34.9B |
KNSAKiniksa Pharmaceuticals, Ltd. | $33.0B |
DSGNDesign Therapeutics, Inc. | $30.8B |
—Talis Biomedical Corporation | $30.6B |
—Forma Therapeutics Holdings, Inc. | $28.8B |
—Zymeworks Inc. | $28.0B |
—bluebird bio, Inc. | $25.0B |
ALGSAligos Therapeutics, Inc. | $24.6B |
OPTEYOpthea Limited | $24.1B |
CRNXCrinetics Pharmaceuticals, Inc. | $23.5B |
XENEXenon Pharmaceuticals Inc. | $23.5B |
—DBV Technologies S.A. | $23.4B |
AXSMAxsome Therapeutics, Inc. | $23.1B |
AVTEAerovate Therapeutics, Inc. | $21.6B |
TSVT*2seventy bio, Inc. | $21.4B |
FLGTFulgent Genetics, Inc. | $20.3B |
—Neoleukin Therapeutics, Inc. | $18.4B |
OTICEUROtonomy, Inc. | $16.3B |
AGLEUSDAeglea BioTherapeutics, Inc. | $16.2B |
BCABBioAtla, Inc. | $16.2B |
SRZNSurrozen, Inc. | $16.1B |
REPLReplimune Group, Inc. | $16.1B |
—DICE Therapeutics, Inc. | $14.9B |
ANABAnaptysBio, Inc. | $14.8B |
TCDA 3.5 05/15/27Tricida, Inc. | $14.8B |
—Affimed N.V. | $14.6B |
698Achilles Therapeutics plc | $13.0B |
CNTACentessa Pharmaceuticals plc | $12.7B |
1T7Tricida, Inc. | $12.3B |
RLMDRelmada Therapeutics, Inc. | $11.2B |
SRPTSarepta Therapeutics, Inc. | $11.1B |
BCELAtreca, Inc. | $10.7B |
—Athira Pharma, Inc. | $10.5B |
ALTAltimmune, Inc. | $9.8B |
—Invitae Corporation | $9.6B |
CYTCyteir Therapeutics, Inc. | $9.2B |
KRTXKaruna Therapeutics, Inc. | $9.2B |
TNGXTango Therapeutics, Inc. | $8.2B |
FGENEURFibroGen, Inc. | $8.2B |
EWTXEdgewise Therapeutics, Inc. | $7.6B |
CBAYUSDCymaBay Therapeutics, Inc. | $7.3B |
MGNXMacroGenics, Inc. | $7.1B |
5E7Iteos Therapeutics, Inc. | $7.0B |
NVV1Novavax, Inc. | $6.9B |
ALLKGUSDAllakos Inc. | $6.9B |
TCRXTScan Therapeutics, Inc. | $6.4B |
RETAEURReata Pharmaceuticals, Inc. | $5.9B |
RVMDRevolution Medicines, Inc. | $5.6B |
HRMYHarmony Biosciences Holdings, Inc. | $5.3B |
NGMUSDNGM Biopharmaceuticals, Inc. | $5.2B |
ALECAlector, Inc. | $4.9B |
ATYRaTyr Pharma, Inc. | $4.7B |
KURAKura Oncology, Inc. | $4.3B |
DNLIDenali Therapeutics Inc. | $4.0B |
BMEABiomea Fusion, Inc. | $3.9B |
—TCR2 Therapeutics Inc. | $3.5B |
—Genetron Holdings Limited | $2.8B |
Page 1 of 2Next